The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
Abstract
Macrocycles are ideal in efforts to tackle "difficult" targets, but our understanding of what makes them cell permeable and orally bioavailable is limited. Analysis of approximately 100 macrocyclic drugs and clinical candidates revealed that macrocycles are predominantly used for infectious disease and in oncology and that most belong to the macrolide or cyclic peptide class. A significant number (N = 34) of these macrocycles are administered orally, revealing that oral bioavailability can be obtained at molecular weights up to and above 1 kDa and polar surface areas ranging toward 250 Å(2). Moreover, insight from a group of "de novo designed" oral macrocycles in clinical studies and understanding of how cyclosporin A and model cyclic hexapeptides cross cell membranes may unlock wider opportunities in drug discovery. However, the number of oral macrocycles is still low and it remains to be seen if they are outliers or if macrocycles will open up novel oral druggable space.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Prediction of Drug Absorption Using Multivariate Statistics
Egan, W. J., Merz, & Baldwin, J. J. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000292e · Cited by 1,970
DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,831
The exploration of macrocycles for drug discovery — an underexploited structural class
Driggers, E. M., Hale, S. P., Lee, J., & Terrett, N. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2590 · Cited by 1,370
Pirsch, J. D., Miller, J., Deierhoi, M. H., Vincenti, F., & Filo, R. S. (1997) · Transplantation · doi:10.1097/00007890-199704150-00013 · Cited by 1,122
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
Lamarre, D., Anderson, P. C., Bailey, M., Beaulieu, P., Bolger, G., Bonneau, P., Bös, M., Cameron, D. R., Cartier, M., Cordingley, M. G., et al. (2003) · Nature · doi:10.1038/nature02099 · Cited by 917
Marsault, E., & Peterson, M. L. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1012374 · Cited by 843
Clinical Pharmacokinetics of Everolimus
Kirchner, G. I., Meier-Wiedenbach, I., & Manns, M. P. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443020-00002 · Cited by 508
Macrocycles In New Drug Discovery
Mallinson, J., & Collins, I. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.93 · Cited by 468
The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review
González Canga, A., Sahagún Prieto, A. M., Diez Liébana, M. J., Fernández Martínez, N., Sierra Vega, M., & García Vieitez, J. J. (2008) · The AAPS Journal · doi:10.1208/s12248-007-9000-9 · Cited by 419
Rezai, T., Bock, J. E., Zhou, M. V., Kalyanaraman, C., Lokey, R. S., & Jacobson, M. P. (2006) · Journal of the American Chemical Society · doi:10.1021/ja063076p · Cited by 416
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Hann, M. M., & Keserü, G. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3701 · Cited by 411
On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds
White, T. R., Renzelman, C. M., Rand, A. C., Rezai, T., McEwen, C. M., Gelev, V. M., Turner, R. A., Linington, R. G., Leung, S. S. F., Kalgutkar, A. S., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.664 · Cited by 386
Perni, R. B., Almquist, S. J., Byrn, R. A., Chandorkar, G., Chaturvedi, P. R., Courtney, L. F., Decker, C. J., Dinehart, K., Gates, C. A., Harbeson, S. L., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.899-909.2006 · Cited by 386
Cyclosporin Clinical Pharmacokinetics
Fahr, A. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324060-00004 · Cited by 356
Alex, A., Millan, D. S., Perez, M., Wakenhut, F., & Whitlock, G. A. (2011) · MedChemComm · doi:10.1039/c1md00093d · Cited by 329
Waring, M. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.109 · Cited by 326
Review of Macrolides and Ketolides: Focus on Respiratory Tract Infections
Zhanel, G. G., Dueck, M., Hoban, D. J., Vercaigne, L. M., Embil, J. M., Gin, A. S., & Karlowsky, J. A. (2001) · Drugs · doi:10.2165/00003495-200161040-00003 · Cited by 304
Clinical Pharmacokinetics of Sirolimus
Mahalati, K., & Kahan, B. D. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140080-00002 · Cited by 302
Ashcroft, D. M., Dimmock, P., Garside, R., Stein, K., & Williams, H. C. (2005) · BMJ · doi:10.1136/bmj.38376.439653.d3 · Cited by 294
Schreiber, S. L. (2009) · Nature · doi:10.1038/457153a · Cited by 292
Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., Patnaik, A., Mathews, L., Ricart, A. D., Mays, T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0345 · Cited by 273
Summa, V., Ludmerer, S. W., McCauley, J. A., Fandozzi, C., Burlein, C., Claudio, G., Coleman, P. J., DiMuzio, J. M., Ferrara, M., Di Filippo, M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-12 · Cited by 259
Getting pharmaceutical R&D back on target
Bunnage, M. E. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.581 · Cited by 258
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
Fricker, G., Drewe, J., Huwyler, J., Gutmann, H., & Beglinger, C. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15612.x · Cited by 223
El Tayar, N., Mark, A. E., Vallat, P., Brunne, R. M., Testa, B., & van Gunsteren, W. F. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00076a002 · Cited by 215
William, A. D., Lee, A. C.-H., Blanchard, S., Poulsen, A., Teo, E. L., Nagaraj, H., Tan, E., Chen, D., Williams, M., Sun, E. T., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200326p · Cited by 201
Lin, T.-I., Lenz, O., Fanning, G., Verbinnen, T., Delouvroy, F., Scholliers, A., Vermeiren, K., Rosenquist, A., Edlund, M., Samuelsson, B., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01058-08 · Cited by 188
Intestinal Permeability of Cyclic Peptides: Common Key Backbone Motifs Identified
Beck, J. G., Chatterjee, J., Laufer, B., Kiran, M. U., Frank, A. O., Neubauer, S., Ovadia, O., Greenberg, S., Gilon, C., Hoffman, A., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja303200d · Cited by 187
Billich, A., Aschauer, H., Aszódi, A., & Stuetz, A. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.07.013 · Cited by 182
Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
McCauley, J. A., McIntyre, C. J., Rudd, M. T., Nguyen, K. T., Romano, J. J., Butcher, J. W., Gilbert, K. F., Bush, K. J., Holloway, M. K., Swestock, J., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9015526 · Cited by 178
Raboisson, P., de Kock, H., Rosenquist, Å., Nilsson, M., Oden, L. S., Lin, T., Roue, N., Ivanov, V., Wähling, H., Wickström, K., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.088 · Cited by 145
Younes, A., Romaguera, J. E., Fanale, M. A., McLaughlin, P. J., Hagemeister, F. B., Copeland, A. R. M., Neelapu, S. S., Kwak, L. W., Shah, J. J., Faria, S. D. C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.5223 · Cited by 143
MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease
Liverton, N. J., Carroll, S. S., DiMuzio, J. M., Fandozzi, C. M., Graham, D. J., Hazuda, D. J., Holloway, M. K., Ludmerer, S. W., McCauley, J. A., McIntyre, C. J., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00677-09 · Cited by 141
Hopkins, S., Scorneaux, B., Huang, Z., Murray, M. G., Wring, S. A., Smitley, C., Harris, R. W., Erdmann, F., Fischer, G. S., & Ribeill, Y. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00660-09 · Cited by 139
Liverton, N. J., Holloway, M. K., McCauley, J. A., et al. (2008) · Journal of the American Chemical Society · doi:10.1021/ja711120r · Cited by 136
Use of 3D Properties to Characterize Beyond Rule-of-5 Property Space for Passive Permeation
Guimarães, C. R. W., Mathiowetz, A. M., Shalaeva, M. Y., Goetz, G. H., & Liras, S. I. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300010y · Cited by 117
Ross, D. B. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078032 · Cited by 115
Targeting mTOR in renal cell carcinoma
Hudes, G. R. (2009) · Cancer · doi:10.1002/cncr.24239 · Cited by 110
Tada, H., Tsuchiya, N., Satoh, S., Kagaya, H., Li, Z., Sato, K., Miura, M., Suzuki, T., Kato, T., & Habuchi, T. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2005.02.073 · Cited by 110
Zotarolimus (ABT-578) eluting stents
Burke, S. E., Kuntz, R. E., & Schwartz, L. B. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.021 · Cited by 98
Edwards, G., Dingsdale, A., Helsby, N. A., Orme, M. L., & Breckenridge, A. (1988) · European Journal of Clinical Pharmacology · doi:10.1007/bf00637608 · Cited by 97
Okumu, F. W., Pauletti, G. M., VanderVelde, D. G., Siahaan, T. J., & Borchardt, R. T. (1997) · Pharmaceutical Research · doi:10.1023/a:1012092409216 · Cited by 94
The Effect of β-Turn Structure on the Passive Diffusion of Peptides Across Caco-2 Cell Monolayers
Knipp, G. T., VanderVelde, D. G., Siahaan, T. J., & Borchardt, R. T. (1997) · Pharmaceutical Research · doi:10.1023/a:1012152117703 · Cited by 88
Hoveyda, H. R., Marsault, É., Gagnon, R., Mathieu, A. P., Vézina, M., Landry, A., Wang, Z., Benakli, K., Beaubien, S., Saint‐Louis, C. J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007062 · Cited by 88
DeLorbe, J. E., Clements, J. H., Whiddon, B. B., & Martin, S. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100142y · Cited by 88
ISATX247: a novel calcineurin inhibitor
Aspeslet, L. J., Freitag, D. G., Trepanier, D. J., Abel, M., Naicker, S. S., Kneteman, N. N., Foster, R. T., & Yatscoff, R. W. (2001) · Transplantation Proceedings · doi:10.1016/s0041-1345(00)02325-3 · Cited by 61
Methods for the synthesis of macrocycle libraries for drug discovery
Terrett, N. K. (2010) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2010.06.002 · Cited by 61
β-Hairpin protein epitope mimetic technology in drug discovery
Obrecht, D., Chevalier, É., Moehle, K., & Robinson, J. A. (2011) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2011.07.006 · Cited by 59
Bogdan, A. R., Davies, N. L., & James, K. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c1ob05996c · Cited by 57
Devogelaere, B., Berke, J. M., Vijgen, L., Dehertogh, P., Fransen, E., Cleiren, E., van der Helm, L., Nyanguile, O., Tahri, A., Amssoms, K., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00245-12 · Cited by 48
Weiss, H., Fresneau, M., Moenius, T., Stuetz, A., & Billich, A. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021915 · Cited by 48
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer
Buckner, J. C., Forouzesh, B., Erlichman, C., Hidalgo, M. M., Boni, J. P., Dukart, G., Berkenblit, A., & Rowinsky, E. K. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9257-1 · Cited by 44
Kirsner, R., Heffernan, M. P., & Antaya, R. J. (2010) · Acta Dermato Venereologica · doi:10.2340/00015555-0748 · Cited by 37
SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis
Madan, B., Goh, K. C., Hart, S., William, A. D., Jayaraman, R., Ethirajulu, K., Dymock, B. W., & Wood, J. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200675 · Cited by 33
Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs
Hosoe, K., Mae, T., Konishi, E., Fujii, K., Yamashita, K., Yamane, T., HIDAKA, T., & Ohashi, T. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.12.2749 · Cited by 29
Konings, I. R. H. M., de Jonge, M. J. A., Burger, H., van der Gaast, A., Beijsterveldt, L. E. C. V., Winkler, H. J. S., Verweij, J., Yuan, Z., Hellemans, P., & Eskens, F. A. L. M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605867 · Cited by 22
Chen, Y., Cabana, B. E., Kivel, N. M., et al. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007300745 · Cited by 16
Cited by
Ilardi, E. A., Vitaku, E., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401375q · Cited by 1,604
Counting on natural products for drug design
Rodrigues, T., Reker, D., Schneider, P., & Schneider, G. (2016) · Nature Chemistry · doi:10.1038/nchem.2479 · Cited by 1,250
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Self-citationA Survey of the Role of Noncovalent Sulfur Interactions in Drug Design
Beno, B. R., Yeung, K.-S., Bartberger, M. D., Pennington, L. D., & Meanwell, N. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501853m · Cited by 772
Tetrazoles via Multicomponent Reactions
Neochoritis, C. G., Zhao, T., & Dömling, A. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00564 · Cited by 599
Metadata
- Authors
- Giordanetto, F., & Kihlberg, J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-09-17
- Volume
- 57
- Issue
- 2
- Pages
- 278-295
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1968711897
- Cited by
- 563
- References
- 62
- FWCI
- 19.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.